This study investigated how abnormally glycosylated IgG from active lupus nephritis (LN) patients causes podocyte injury via the CLEC7A–SYK signaling axis, using human podocyte cultures, kidney biopsies, and MRL/lpr mouse kidneys.
LN-IgG (but not healthy control IgG or IgG from SLE patients without nephritis) activated CLEC7A and SYK in podocytes, causing cytoskeleton disruption, reduced nephrin expression, and impaired motility. Deglycosylation of LN-IgG blocked these effects. Pharmacological SYK inhibition or CLEC7A silencing prevented podocyte injury. Elevated CLEC7A and SYK expression was confirmed in kidney biopsies from active LN patients and MRL/lpr mice.
Sample sizes for patient biopsies and IgG donor cohorts are not reported in the abstract. The study is largely mechanistic (in vitro and animal models), so direct clinical translation is unproven. MRL/lpr mice do not fully replicate human LN pathology.
The IgG glycosylation–CLEC7A–SYK axis is a potential therapeutic target in LN; SYK inhibitors already in clinical use may warrant evaluation specifically in patients with active, IgG-driven nephritis.
Explore related topics
